| scholarly article | Q13442814 |
| P2093 | author name string | Imad A Tabbara | |
| Hady Ghanem | |||
| Niki Tank | |||
| P2860 | cites work | Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia | Q24290910 |
| Nucleophosmin acts as a novel AP2alpha-binding transcriptional corepressor during cell differentiation | Q24298255 | ||
| The role of FLT3 in haematopoietic malignancies | Q24319174 | ||
| Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 | ||
| Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study | Q24643738 | ||
| DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome | Q24644436 | ||
| DNMT3A Mutations in Acute Myeloid Leukemia | Q27559610 | ||
| CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations | Q27824809 | ||
| Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype | Q27824827 | ||
| RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years | Q27824840 | ||
| Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations | Q27824843 | ||
| Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype | Q27824844 | ||
| Implications of NRAS mutations in AML: a study of 2502 patients | Q27824859 | ||
| Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). | Q27824861 | ||
| The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia | Q27851416 | ||
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia | Q27851430 | ||
| Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study | Q27851436 | ||
| Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party | Q27851437 | ||
| Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. | Q27851460 | ||
| Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. | Q27851476 | ||
| Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study | Q27851545 | ||
| Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor | Q27851558 | ||
| Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study | Q27851561 | ||
| Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia | Q27851562 | ||
| Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value | Q27851569 | ||
| IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status | Q27851581 | ||
| TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study | Q27851621 | ||
| Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. | Q45929224 | ||
| Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis | Q46549470 | ||
| Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia | Q47290549 | ||
| Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia. | Q47830267 | ||
| Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics | Q47935030 | ||
| BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). | Q48396875 | ||
| BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications | Q48684574 | ||
| Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. | Q50554670 | ||
| Increased AF1q gene expression in high-risk myelodysplastic syndrome. | Q53279719 | ||
| The clinical significance of karyotype in acute myelogenous leukemia. | Q53408893 | ||
| Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. | Q54465378 | ||
| Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. | Q54501898 | ||
| Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. | Q54510345 | ||
| High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. | Q54546717 | ||
| WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. | Q54682896 | ||
| Frequency and Heritability ofWT1Mutations in Nonsyndromic Wilms' Tumor Patients: A UK Children’s Cancer Study Group Study | Q57272222 | ||
| Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization | Q57291838 | ||
| Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1) | Q57740694 | ||
| The prognostic significance of IDH2 mutations in AML depends on the location of the mutation | Q27851649 | ||
| TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics | Q27851661 | ||
| High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients | Q28209409 | ||
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 | ||
| The protein Id: a negative regulator of helix-loop-helix DNA binding proteins | Q28237471 | ||
| A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG | Q28252253 | ||
| Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines | Q28281211 | ||
| Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias | Q28301353 | ||
| A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. | Q33716570 | ||
| IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study | Q33897586 | ||
| The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. | Q34175340 | ||
| Cytogenetics in acute leukemia | Q34304230 | ||
| The 1,25(OH)2D3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation. | Q34418458 | ||
| The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial | Q34517235 | ||
| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite | Q34517403 | ||
| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis | Q34523534 | ||
| BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study | Q34541748 | ||
| No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. | Q34559865 | ||
| Age and acute myeloid leukemia | Q34564663 | ||
| Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. | Q34568861 | ||
| Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study | Q34593276 | ||
| MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. | Q34627288 | ||
| Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia | Q34630212 | ||
| A clinical overview of WT1 gene mutations | Q34738955 | ||
| Genetics of myeloid leukemias | Q34795893 | ||
| Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome | Q34930673 | ||
| Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study | Q35839909 | ||
| Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. | Q36141686 | ||
| Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. | Q36303442 | ||
| Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. | Q36390379 | ||
| Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation | Q36498807 | ||
| Nucleophosmin and cancer | Q36516405 | ||
| Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features | Q36606696 | ||
| High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CAL | Q36677320 | ||
| Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances | Q36719212 | ||
| The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis | Q36831216 | ||
| Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells | Q36843769 | ||
| Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis | Q37089529 | ||
| Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study | Q37119445 | ||
| Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics | Q37240557 | ||
| The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. | Q37354544 | ||
| Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study | Q38319029 | ||
| Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. | Q38343881 | ||
| Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias | Q38347392 | ||
| Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia | Q38347620 | ||
| FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations | Q39513601 | ||
| Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group | Q39752289 | ||
| EVI1 induces myelodysplastic syndrome in mice | Q39951095 | ||
| Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer | Q40599938 | ||
| Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays | Q42820711 | ||
| The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status | Q42962021 | ||
| Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group | Q42972388 | ||
| IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication | Q43010371 | ||
| A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial | Q43074202 | ||
| Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. | Q43185220 | ||
| Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information | Q43649404 | ||
| Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial | Q43718516 | ||
| Integrative prognostic risk score in acute myeloid leukemia with normal karyotype | Q43816333 | ||
| High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics | Q44034346 | ||
| Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia | Q44073895 | ||
| Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit | Q44142819 | ||
| Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. | Q44189526 | ||
| Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. | Q44240279 | ||
| Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. | Q44401465 | ||
| BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study | Q44443179 | ||
| Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia | Q44646947 | ||
| Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). | Q44758612 | ||
| Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia | Q45073090 | ||
| ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays | Q45113427 | ||
| Risk assessment in patients with acute myeloid leukemia and a normal karyotype | Q45299096 | ||
| High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. | Q45915572 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 69-77 | |
| P577 | publication date | 2011-11-10 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics | |
| P478 | volume | 87 |
| Q33903024 | Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis |
| Q38099426 | Acute myeloid leukemia: advances in diagnosis and classification |
| Q42941264 | Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient |
| Q33409558 | Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia |
| Q39888679 | Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia |
| Q47965783 | Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase |
| Q51069547 | NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. |
| Q43685374 | Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia |
| Q27690776 | Next generation sequencing of acute myeloid leukemia: influencing prognosis |
| Q39450821 | Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia |
| Q47140916 | Sequence variations of mitochondrial DNA D-loop region in patients with acute myeloid leukemia |
| Q64240396 | Wilms Tumor-1 (WT1) rs16754 Polymorphism and Clinical Outcome in Acute Myeloid Leukemia |
Search more.